Status:
COMPLETED
Phase II Study Using Thalidomide for the Treatment of ALS
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Collaborating Sponsors:
Celgene Corporation
Conditions:
Amyotrophic Lateral Sclerosis
ALS
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The use of Thalidomide in patients with ALS who have disease progression.
Detailed Description
Phase II open labeled trial testing the efficacy of thalidomide for ALS in the setting of disease progression.
Eligibility Criteria
Inclusion
- Clinically proven ALS
- Disease duration less than or equal to 5 years
- ALSFRS-R score equal to or greater then 30
Exclusion
- Patients with known deep venous thrombosis or hyper coagulable state will be excluded
- Patients with FVC less than 80%
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2007
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00140452
Start Date
February 1 2005
End Date
November 1 2007
Last Update
November 21 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dartmouth Hichcock Medical Center
Lebanon, New Hampshire, United States, 03756